TY - JOUR
T1 - Relevance of N6-methyladenosine regulators for transcriptome
T2 - Implications for development and the cardiovascular system
AU - Sweaad, Walid Khalid
AU - Stefanizzi, Francesca Maria
AU - Chamorro-Jorganes, Aránzazu
AU - Devaux, Yvan
AU - Emanueli, Costanza
AU - on behalf of EU-CardioRNA COST Action CA17129
N1 - Funding Information:
This work is funded by British Heart Foundation Programme Grant and Personal Chair Awards ( RG/15/5/31446 and CH/15/1/31199 to CE), Diabetes UK (Diabetes UK 16/0005564 to CE, supporting the PhD studentship of W.K.S and Diabetes UK 18/0005874 grant to A.C.), Luxemburg National Research Fund (grants # C14/BM/8225223 , COVID-19/2020-1/14719577/miRCOVID to Y.D. and C17/BM/11613033 to Y.D., supporting the PhD studentship of F.M.S.), Luxemburg Ministry of Higher Education and Research (to Y.D.), Luxemburg Heart Foundation – Daniel Wagner of Luxembourg (to Y.D.).
Funding Information:
This article is based upon work from EU-CardioRNA COST Action CA17129 ( www.cardiorna.eu ) supported by COST (European Cooperation in Science and Technology).
Publisher Copyright:
© 2021
PY - 2021/11
Y1 - 2021/11
N2 - N6-methyladenosine (m6A) is the most abundant and well-studied internal modification of messenger RNAs among the various RNA modifications in eukaryotic cells. Moreover, it is increasingly recognized to regulate non-coding RNAs. The dynamic and reversible nature of m6A is ensured by the precise and coordinated activity of specific proteins able to insert (“write”), bind (“read”) or remove (“erase”) the m6A modification from coding and non-coding RNA molecules. Mounting evidence suggests a pivotal role for m6A in prenatal and postnatal development and cardiovascular pathophysiology. In the present review we summarise and discuss the major functions played by m6A RNA methylation and its components particularly referring to the cardiovascular system. We present the methods used to study m6A and the most abundantly methylated RNA molecules. Finally, we highlight the possible involvement of the m6A mark in cardiovascular disease as well as the need for further studies to better describe the mechanisms of action and the potential therapeutic role of this RNA modification.
AB - N6-methyladenosine (m6A) is the most abundant and well-studied internal modification of messenger RNAs among the various RNA modifications in eukaryotic cells. Moreover, it is increasingly recognized to regulate non-coding RNAs. The dynamic and reversible nature of m6A is ensured by the precise and coordinated activity of specific proteins able to insert (“write”), bind (“read”) or remove (“erase”) the m6A modification from coding and non-coding RNA molecules. Mounting evidence suggests a pivotal role for m6A in prenatal and postnatal development and cardiovascular pathophysiology. In the present review we summarise and discuss the major functions played by m6A RNA methylation and its components particularly referring to the cardiovascular system. We present the methods used to study m6A and the most abundantly methylated RNA molecules. Finally, we highlight the possible involvement of the m6A mark in cardiovascular disease as well as the need for further studies to better describe the mechanisms of action and the potential therapeutic role of this RNA modification.
KW - cardiovascular disease
KW - development
KW - long non-coding RNA
KW - m6A RNA modifications
KW - mRNA
KW - microRNA
UR - http://www.scopus.com/inward/record.url?scp=85109841573&partnerID=8YFLogxK
UR - https://www.ncbi.nlm.nih.gov/pubmed/33991529
U2 - 10.1016/j.yjmcc.2021.05.006
DO - 10.1016/j.yjmcc.2021.05.006
M3 - Article
C2 - 33991529
AN - SCOPUS:85109841573
SN - 0022-2828
VL - 160
SP - 56
EP - 70
JO - Journal of Molecular and Cellular Cardiology
JF - Journal of Molecular and Cellular Cardiology
ER -